Inhibitor Development against p7 Channel in Hepatitis C Virus

Abstract

Hepatitis C Virus (HCV) is the key cause of chronic and severe liver diseases. The recent direct-acting antiviral agents have shown the clinical success on HCV-related diseases, but the rapid HCV mutations of the virus highlight the sustaining necessity to develop new drugs. p7, the viroporin protein from HCV, has been sought after as a potential anti-HCV drug target. Several classes of compounds, such as amantadine and rimantadine have been testified for p7 inhibition. However, the efficacies of these compounds are not high. Here, we screened some novel p7 inhibitors with amantadine scaffold for the inhibitor development. The dissociation constant (Kd) of 42 ARD-series compounds were determined by nuclear magnetic resonance (NMR) titrations. The efficacies of the two best inhibitors, ARD87 and ARD112, were further confirmed using viral production assay. The binding mode analysis and binding stability for the strongest inhibitor were deciphered by molecular dynamics (MD) simulation. These ARD-series compounds together with 49 previously published compounds were further analyzed by molecular docking. Key pharmacophores were identified among the structure-similar compounds. Our studies suggest that different functional groups are highly correlated with the efficacy for inhibiting p7 of HCV, in which hydrophobic interactions are the dominant forces for the inhibition potency. Our findings provide guiding principles for designing higher affinity inhibitors of p7 as potential anti-HCV drug candidates.

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

“…temsirolimus (predicted pIC50 = 11.06), an antineoplastic agent is reported to be in phase II trial for the advanced hepatocellular carcinoma treatment [55] . Similarly, from NS5A predicted drugs, rimantadine (predicted pIC50 = 11.06) a RNA synthesis inhibitor, is experimentally tested as HCV viroporin inhibitor [56] . Vildagliptin (predicted pIC50 = 11.06) a dipeptidyl peptidase 4 inhibitor, is experimentally validated for its activity against hepatocellular carcinoma progression [57] .…”